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Introduction: Local treatment that includes surgical resection of
metastatic pulmonary tumors is controversial because of the biologic
features and invasiveness of these tumors. We report our experience
with a premeditated treatment involving combined computed to-
mography-guided radiofrequency ablation and surgical resection in
three patients with metastatic pulmonary tumors.
Methods: Three patients underwent radiofrequency ablation in
conjunction with surgical resection. The first was a 67-year-old man
with pulmonary metastases of bronchial adenoid cystic carcinoma.
We performed partial resection of five tumors in the right lung and
ablated a tumor in the left lung. The second was a 66-year-old man
with pulmonary metastases of renal cell carcinoma. He underwent
radiofrequency ablation for three tumors in the right upper and
middle lobes, and right lower lobectomy for tumors in that lobe. The
third was a 55-year-old man with pulmonary metastases of high-
grade sarcoma of the right thigh. We performed partial resection of
five tumors in the left lung and ablated a tumor in the right lung.
Results: Two patients had metastatic lesions on both sides of the
lung; we performed surgical resection on one side and radiofre-
quency ablation contralaterally to avoid bilateral thoracotomy. The
third patient underwent surgical resection and radiofrequency abla-
tion to avoid highly invasive right pneumonectomy. All patients
survived for more than 11⁄2 years after combination therapy.
Conclusions: Premeditated treatment involving a combination of
radiofrequency ablation and surgical resection can be a useful option
in patients with metastatic pulmonary tumors, improving curability
and avoiding highly invasive procedures.
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Despite recent medical advances, the prognosis of meta-static pulmonary tumors is still poor, perhaps because of
their biologic features. Most pulmonary metastases arise from
the hematogenous spread of malignant cells, and the lung is
considered to be the first filter for malignant cells in most
primary cancers. In selected patients, local treatment that in-
cludes surgical resection of these tumors is considered a contro-
versial but acceptable option. Especially in nonsurgical candi-
dates, treatment options are limited to chemotherapy with or
without radiation therapy. Nevertheless, no effective chemother-
apy regimen has been proposed for most metastatic pulmonary
tumors, and therefore we must find alternative modalities.
Since the early 1990s, percutaneous radiofrequency
ablation (RFA) has been one of the more successful options
for the treatment of solid malignant tumors in various organs,
especially the liver, because of its minimal invasiveness.1–6
RFA of pulmonary tumors was first reported in 20007 and has
become a promising treatment option for patients who are not
surgical candidates.
We have treated patients with metastatic pulmonary tu-
mors using a premeditated treatment involving RFA in conjunc-
tion with surgical resection, as there is potential for local control
with these two modalities. In this article, we propose a new
treatment option for metastatic pulmonary tumors.
PATIENTS AND METHODS
Percutaneous RFA was performed in patients with
intrathoracic malignancies between June 2001 and April 2006
in Okayama University Hospital. The RFA technique has
been described previously.8–10 The study was conducted with
the approval of our institutional Human Studies Committee
on June 12, 2001, and written informed consent was obtained
from all patients.
In brief, RFA is usually performed under local anes-
thesia and sedation with intravenous fentanyl or epidural
anesthesia, if necessary. Patients are monitored by continuous
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pulse oximetry, electrocardiography, and blood pressure mea-
surement. The placement of the radiofrequency electrode is
confirmed by computed tomographic fluoroscopy. We usually
use two types of electrodes coupled to a radiofrequency gener-
ator and a perfusion pump (Cool-tip RF system, 17-gauge
internally cooled electrodes; Radionics/ValleyLab, Boulder,
CO) or a LeVeen Needle Electrode (17-gauge multitined ex-
pandable electrodes with an RF 3000 generator; RadioThera-
peutics Corp., Sunnyvale, CA, distributed by Boston Scientific,
Natick, MA). The electric current was grounded by applying
four grounding pads to the opposite chest wall.
A total of 229 patients underwent 389 RFA sessions
applied for 637 lesions. Of these 229 patients, 188 (82.1%)
who received RFA had metastatic pulmonary lesions,
whereas 41 (17.9%) had primary lung carcinomas. All pa-
tients were nonsurgical candidates because they were at high
risk for surgery, or had refused surgery, or because of the
extent of their disease. The hospital observation period after
RFA was 24 hours for most patients without any complica-
tions. Three patients underwent RFA in conjunction with
surgical resection in this series.
The first patient, 67-year-old man, was diagnosed with
bronchial adenoid cystic carcinoma and underwent sleeve
resection of the bronchus in 1994. A metastatic tumor in the
right lung was revealed on follow-up chest computed tomog-
raphy (CT) in 1999, for which partial resection of the lung
with adjuvant chemotherapy was performed. Approximately
1 year later, there was a new lesion in the left lung, and he
underwent partial resection by video-assisted thoracic sur-
gery. In 2003, six metastatic lung tumors on both sides were
revealed on follow-up CT (five tumors on the right side and
one on the left) (Figure 1A–E1). Bone scintigraphy and
magnetic resonance imaging of the brain revealed no other
metastatic lesions. The patient was not considered a candidate
for surgical resection in both lungs because of the extent of
the disease and poor respiratory function because of his
history of multiple pulmonary resections. Surgical resection
of the five tumors in the right lung followed by percutaneous
RFA for the tumor in the left lung was considered the best
option for local tumor eradication. We performed partial
resection of the five tumors in the right lung on August 15,
2003 and ablated the tumor in the left lung (left S8, 27  23
mm) on September 9, 2003 (Figure 1E–2). Ablation was done
three times using a Cool-tip electrode (total time 34 minutes,
maximum power 117 W) under local anesthesia.
The second patient, a 66-year-old man, was diagnosed
with renal cell carcinoma after presenting with hematuria in
August 1995; he underwent left nephrectomy in September
1995. His medical history included diabetes mellitus, hyper-
tension, and arrhythmia. A chest radiograph taken during a
check-up in September 2002 revealed a nodule in the right
lung, which was biopsied and found to be a metastatic lesion
from the renal cell carcinoma. He then received immunother-
apy with interferon. In September 2004, a follow-up CT
revealed metastatic tumors in the right lung (Figure 2A–D).
We considered it imperative for him to avoid right pneumo-
nectomy, because of his comorbid conditions. Percutaneous
RFA for three tumors in the right upper and middle lobes
FIGURE 1. A 67-year-old man with
pulmonary metastases from bronchial
adenoid cystic carcinoma. A, B, C, D,
E-1, CT scans of the chest show meta-
static tumors in both lungs. E-2, CT
scan obtained during radiofrequency
ablation shows the position of the
electrode in the tumor.
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(right S1, S4, and S5) followed by surgical resection of
tumors in the right lower lobe was thought to be the best
option for local tumor eradication. In October 2004, we
performed RFA for the three tumors in the right upper and
middle lobes (Figure 2A–C); in November 2004 we per-
formed right lower lobectomy as complete resection, because
the tumors extended to the right hilum (Figure 2D). The
ablations were performed under local anesthesia as follows:
for the S1 tumor (20 17 mm), Cool-tip electrode, total time
14 minutes, maximum power 60 W; for the S4 tumor (9  9
mm), LeVeen electrode, total time 9 minutes, maximum
power 60 W; for the S5 tumor (24  18 mm), LeVeen
electrode, total time 33 minutes, maximum power 90 W.
The third patient was a 55-year-old man with a history
of high-grade sarcoma of the right thigh that was treated with
wide resection in August 2005. He received chemotherapy
(ICE-T with interferon) and radiotherapy after the surgical
procedure. In January 2006, a follow-up CT revealed six
metastatic lung tumors (five on the left side and one on the
right) (Figure 3), with no evidence of metastases in other
organs. He also had a medical history of Von Recklinghausen
disease (neurofibromatosis-1). We considered combined ther-
apy with surgical resection and RFA because of the low
invasiveness of this procedure. Thus, we performed partial
resection of the five tumors in the left lung on February 6,
2006 and ablated a tumor in the right lung (S6, 5 5 mm) on
February 22, 2006 (Figure 3A–E-1). The ablation was done
three times using a LeVeen electrode (total time 19 minutes,
maximum power 25 W) under local anesthesia (Figure 3E-2).
RESULTS
No pneumothoraces were seen in two of the patients
after RFA, whereas the third patient developed a small
pneumothorax that did not require treatment. No other com-
plications or side effects (e.g., pleural effusion, pleurisy,
relevant bleeding, high fever, and severe pain requiring med-
ication) occurred during or after RFA in any of the three
patients. There were also no complications or side effects
after surgery and all of the patients returned to their normal
daily activities.
The first patient remained asymptomatic on clinical
examination approximately 9 months after the RFA; how-
ever, contrast-enhanced CT revealed a right hilar lymph
nodal swelling and regrowth with partial enhancement of the
ablated tumor. Therefore, repeat RFA was performed in this
region. Since the repeat RFA, he has been receiving chemo-
therapy (cisplatin  S-1), and is alive with right hilar lymph
node and pulmonary metastases approximately 4 years after
the combination therapy, with no evidence of viability of the
ablated tumor by contrast-enhanced CT scan.
In the second patient, follow-up CT 3 months after the
RFA showed three new metastatic tumors on both sides of
the lungs, with no signs of progression of the ablated tumors. He
underwent repeat RFA for these three tumors. CT done 5
months after the second RFA revealed some pleural dissemina-
tion in the right pleural cavity. He underwent embolization of the
inferior phrenic arteries, and is alive with tumors approximately
1 year and 8 months after the combination therapy.
The third patient is alive and well without any signs of
recurrence or metastases detected by follow-up CT scans
approximately 1 year and 6 months after the combination
therapy.
DISCUSSION
In most patients with metastatic pulmonary disease,
malignant cells are considered to disseminate in the blood-
stream. In these circumstances, removing the tumors by local
treatment such as surgical resection is usually not beneficial.
Systemic therapies, such as chemotherapy, should be the
treatment of first choice, but these are not usually effective in
curing patients or prolonging their survival. For years, inves-
FIGURE 2. A 66-year-old man with pulmonary metastases
from renal cell carcinoma. A–C, CT scans of the chest ob-
tained during radiofrequency ablation show the position of
the electrode in three tumors in the right upper and middle
lobes (right S1, S4, and S5). D, CT scan of the chest shows
metastatic tumors in the right lower lobe.
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tigators have reported that surgical resection (metastasec-
tomy) is a significant therapeutic option for metastatic pulmo-
nary tumors, to improve long-term survival.11–14 In 1965,
Thomford et al.15 originally reported the criteria for selecting
patients for surgical resection of metastatic tumors in the lungs
as follows1: the patient must be a good risk for surgical inter-
vention2; the primary malignancy is controlled3; there is no
evidence of metastatic disease elsewhere in the body; and4
roentgenologic evidence of pulmonary metastasis is limited to
one lung. These criteria have been accepted by many surgeons
for years, though the indications have been expanded because of
surgical and technological advances. For example, resection of
multiple lesions or bilateral lesions remains controversial; how-
ever, it is acceptable to many surgeons.
In this series, we encountered three patients who un-
derwent combined therapy with surgical resection and RFA.
Two cases had metastatic lesions in both lungs; we performed
surgical resection on one side and RFA on the contralateral side
to avoid highly invasive bilateral thoracotomy. We also came
across a patient who underwent surgical resection of a string of
tumors and RFA for a solitary tumor to avoid highly invasive
right pneumonectomy. All of these patients survived more than
1 year after the combination therapy; however, two are alive
with tumors. It appears to be important that the patients selected
should be suitable for this therapeutic option.
The most important factor to consider regarding local
treatment for metastatic pulmonary tumors is whether cura-
tive local control is possible. It is believed that the strongest
predictor of survival is completeness of resection, and that the
greater the number of metastatic lesions, the lower the prob-
ability of complete resection.
The Internal Registry of Lung Metastases, which was
established in 1991 to assess the long-term results of pulmo-
nary metastasectomy, has accrued 5206 cases.16 The results
confirm that metastasectomy is a potentially curative treat-
ment that can be administered safely with low mortality.
Consideration of resectability, disease-free interval, and the
number of metastases enabled us to design a simple system of
classification valid for different tumor types.
It has been reported that surgical resection of pulmo-
nary metastases from colorectal carcinoma,17 renal cell car-
cinoma,18 osteosarcoma,19 soft tissue sarcoma,11 hepatocellu-
lar carcinoma,12 and breast carcinoma20 can be beneficial
even in patients with multiple pulmonary lesions.
Use of surgical resection in patients with bilateral
pulmonary metastases is also controversial because of the
invasiveness of bilateral thoracotomy. Several studies have
reported that patients with pulmonary metastasis limited to
one lung have a better prognosis than those with both lungs
affected21; however, some studies have found no difference in
FIGURE 3. A 55-year-old man with pul-
monary metastases of high-grade sar-
coma of the right thigh. A, B, C, D, E-1,
CT scans of the chest show metastatic
tumors in both lungs. E-2, CT scan ob-
tained during radiofrequency ablation
shows the position of the electrode in
the tumor.
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survival among patients with unilateral or bilateral metasta-
ses.11,13,17,22 These findings suggest that percutaneous RFA
may play a useful role in selected patients with pulmonary
metastases, especially because it avoids the need for bilateral
thoracotomy.
In patients with larger pulmonary tumors, RFA did not
seem to be effective. In fact, 70% of patients with lesions of
3 cm succumbed to their disease within the first 14
months.23 We previously reported that greater tumor size was
an independent risk factor for local progression of ablated
tumors.9 In contrast, with RFA the size of pulmonary metas-
tases is usually not prognostic for survival after surgical
resection. Therefore, the risk of failure of lung RFA needs to
be considered in patients with large pulmonary lesions. In
addition, some lesions were adjacent to large vessels or
bronchi, which produce a “heat sink” effect by decreasing
thermal energy.24,25 This phenomenon seems to protect these
vessels or bronchi from heat injury, and at the same time
prevents perivascular or peribronchiolar tissue necrosis.
When considering strategies for local control of meta-
static pulmonary tumors, we need to know their advantages
and disadvantages. The advantages and disadvantages of
surgical resection and RFA are summarized in Table 1.
RFA and stereotactic radiotherapy have been accepted
as alternative therapeutic tools for treating unresectable pul-
monary malignancies. Moreover, stereotactic radiotherapy is
a novel modality that not only overcomes certain limitations
imposed by standard radiation therapy but also permits delivery
of higher radiation doses to the target lung tumor. The incidence
of complications and success rates does not differ greatly in
patients treated with percutaneous RFA or stereotactic radiother-
apy for unresectable pulmonary malignancies26; however, no
consensus exists for the preferential use of either of the thera-
peutic modalities. As both modalities have advantages as well as
disadvantages, their comparison should be evaluated by means
of randomized controlled studies.
Another combined local therapy using two different
modalities that included RFA was reported recently. Dupuy
and colleagues demonstrated a potential benefit of percuta-
neous RFA followed by radiotherapy in patients with inop-
erable stage I or II non-small cell lung cancer.27,28 They
suggested that the combination therapy might improve the
likelihood of local control. We also consider this combination
therapy to be useful in increasing the local control rate in
large pulmonary lesions.
CONCLUSIONS
If the advantages and disadvantages of RFA and sur-
gical resection are understood, combination therapy with
these modalities can become a useful option in selected
patients with metastatic pulmonary tumors, improving cur-
ability and avoiding highly invasive procedures.
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